Neoadjuvant chemoradiation versus perioperative chemotherapy followed by surgery in resectable adenocarcinomas of the esophagogastric junction: A retrospective single center analysis

Schulze,Björn; Bergis,Dominik; Balermpas,Panagiotis; Trojan,Jörg; Woeste,Guido; Bechstein,Wolf Otto; Rödel,Claus; Weiss,Christian

doi:10.3892/ol.2013.1709

Neoadjuvant chemoradiation versus perioperative chemotherapy followed by surgery in resectable adenocarcinomas of the esophagogastric junction: A retrospective single center analysis

Authors:
- Björn Schulze
- Dominik Bergis
- Panagiotis Balermpas
- Jörg Trojan
- Guido Woeste
- Wolf Otto Bechstein
- Claus Rödel
- Christian Weiss
View Affiliations

Affiliations: Department of Radiation Oncology, Johann Wolfgang Goethe University Hospital, Frankfurt 60590, Germany, Department of Gastroenterology, Johann Wolfgang Goethe University Hospital, Frankfurt 60590, Germany, Department of General, Visceral and Transplantation Surgery, Johann Wolfgang Goethe University Hospital, Frankfurt 60590, Germany
Published online on: November 27, 2013 https://doi.org/10.3892/ol.2013.1709
Pages: 534-540

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The current study presents a retrospective comparison, performed at a single academic center, of preoperative chemoradiation (CRT) and perioperative chemotherapy (CT) in addition to surgery in locally advanced but resectable adenocarcinoma of the esophagogastric junction (AEG). A total of 29 consecutive patients with locally advanced AEGs were retrospectively analyzed. Treatment consisted of preoperative CRT (mean dose, 45.0 Gy) plus two cycles of CT with cisplatin and 5‑FU or perioperative CT with epirubicin, cisplatin and capecitabine (three cycles preoperatively and postoperatively). Within four to six weeks following preoperative treatment, surgical therapy was performed. Median overall survival was 21.0 months in the perioperative CT group versus 41.7 months in the CRT group [P=0.36; hazard ratio (HR), 1.50; 95% confidence interval (CI), 0.58‑3.84]. Three‑year survival rates were 55 and 38%, respectively, in favor of the CRT group, and progression‑free survival was 20.0 months in the CT group compared with 24.1 months in the CRT group (P=0.71; HR, 1.19; 95% CI, 0.46‑3.05). The total number of major surgical complications was almost equal in the two groups. Margin‑free resections were achieved in all patients of the CRT group, but only 76.9% of the CT group (P=0.05). In addition, significantly higher R0 resection rates and an increased number of pathological complete remissions were demonstrated in the CRT group compared with those of the CT group. These results appear to indicate a trend for improved progression‑free and overall survival for the CRT group. As postoperative morbidity and mortality rates were similar in the two groups, the results support the use of CRT for patients with advanced AEG tumors.

View Figures

View References

1	Pera M: Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction. Recent Results Cancer Res. 155:1–14. 2000. View Article : Google Scholar : PubMed/NCBI
2	Trivers KF, Sabatino SA and Stewart SL: Trends in esophageal cancer incidence by histology, United States, 1998–2003. Int J Cancer. 123:1422–1428. 2008.
3	Breaux JR, Bringaze W, Chappuis C and Cohn I Jr: Adenocarcinoma of the stomach: a review of 35 years and 1,710 cases. World J Surg. 14:580–586. 1990.PubMed/NCBI
4	Allum WH, Stenning SP, Bancewicz J, Clark PI and Langley RE: Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 27:5062–5067. 2009. View Article : Google Scholar : PubMed/NCBI
5	Burmeister BH, Smithers BM, Gebski V, et al; Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 6:659–668. 2005. View Article : Google Scholar
6	Burmeister BH, Thomas JM, Burmeister EA, et al: Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer. 47:354–360. 2011. View Article : Google Scholar
7	Kelsen DP, Ginsberg R, Pajak TF, et al: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 339:1979–1984. 1998. View Article : Google Scholar
8	Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A and Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 19:305–313. 2001.
9	Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N and Hennessy TP: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 335:462–467. 1996. View Article : Google Scholar : PubMed/NCBI
10	van Hagen P, Hulshof MC, van Lanschot JJ, et al; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 366:2074–2084. 2012.
11	Stahl M, Walz MK, Stuschke M, et al: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 27:851–856. 2009. View Article : Google Scholar
12	Sjoquist KM, Burmeister BH, Smithers BM, et al; Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 12:681–692. 2011. View Article : Google Scholar
13	Lutz MP, Zalcberg JR, Ducreux M, et al; First St Gallen EORTC Gastrointestinal Cancer Conference 2012 Expert Panel. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer. 48:2941–2953. 2012. View Article : Google Scholar
14	Siewert JR, Hölscher AH, Becker K and Gössner W: Cardia cancer: attempt at a therapeutically relevant classification. Chirurg. 58:25–32. 1987.(In German).
15	Cunningham D, Allum WH, Stenning SP, et al; MAGIC Trials Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
16	Ychou M, Boige V, Pignon JP, et al: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 29:1715–1721. 2011. View Article : Google Scholar
17	Tepper J, Krasna MJ, Niedzwiecki D, et al: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 26:1086–1092. 2008. View Article : Google Scholar
18	Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 359:1727–1733. 2002. View Article : Google Scholar : PubMed/NCBI
19	Leibl BJ, Vitz S, Schäfer W, Alfrink M, Gschwendtner A and Grabenbauer GG: Adenocarcinoma of the esophagogastric junction: neoadjuvant radiochemotherapy and radical surgery: early results and toxicity. Strahlenther Onkol. 187:231–237. 2011. View Article : Google Scholar
20	Starling N, Okines A, Cunningham D, et al: A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. Br J Cancer. 100:1725–1730. 2009. View Article : Google Scholar